热门资讯> 正文
Viridian Therapeutics因2.25亿美元证券发行定价下滑
2024-09-12 14:12
- Viridian Therapeutics (NASDAQ:VRDN) shares dropped 2% after-hours on Wednesday after the biotechnology company priced an upsized underwritten public offering of common stock and preferred stock, comprising ~10.67M shares of common stock, issued at $18.75/share, and 20,000 shares of series B non-voting convertible preferred stock issued at $1,250.06250/share, which is convertible into ~1.33M shares of common stock.
- In addition, Viridian (VRDN) has granted the underwriters a 30-day option to purchase an additional 1.8 million shares of common stock at the public offering price.
- The gross proceeds from the offering are estimated to be $225M; net proceeds will be used to support the company's clinical development programs, as well as for working capital and general corporate purposes.
- All shares to be sold in the underwritten public offering are being offered by Viridian (VRDN).
- The offering is expected to close on or about September 13, 2024.
More on Viridian Therapeutics
- Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
- Viridian Therapeutics: Key Inflection Points Ahead
- Viridian hits five-month high after trial data for lead asset (update)
- Seeking Alpha’s Quant Rating on Viridian Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
